I have missed a few post's lately because i dont have the time to sift through every single
"oh no, prima just dropped .05", or "I THINK" this and "I THINK "that, so i'm not sure weather this has been noted yet.
Thought i would post it under this thread so that only those who really care about long term will read it, and not just the free riders in it to make a few bucks.
Anyway, good luck to all the LONG TERMERS.
TriMarkPublications.com cites in its newly published
"Cancer Vaccines Markets" report that the cancer vaccines market will catapult to over $7 billion by 2015.
For more information, visit: http://www.trimarkpublications.com/products/Cancer-Vaccines-Markets.html.
Cancer vaccines can be divided into six main categories: antigen/adjuvant vaccines,
DNA vaccines, vector-based vaccines,
tumor cell vaccines,
dendritic cell vaccines and anti-idiotype vaccines.
The FDA's first approval of a therapeutic
cancer vaccine in 2010 has demonstrated
the potential for these novel types of
treatments to successfully enter a major market.
The cancer vaccines market is driven by
the potential for cancer vaccines to be used with existing cancer therapeutics,
their possibility of being used as long-term treatments,
and their status as niche products fulfilling unmet therapeutic needs.
The "Cancer Vaccines Markets" report covers:
Antigen/Adjuvant Vaccines
DNA Vaccines
Prophylactic Vaccines
Therapeutic Vaccines
Tumor Cell Vaccines
Dendritic Cell (DC) Vaccines
Anti-Idiotype Vaccines
Cervical Cancer (HPV)
Breast Cancer
Screening and Cancer Detection
Immune Response
Personalized Medicine
Combination Therapies
Pharmaceutical Product Regulation
New Drug Application (NDA)
Biologics License Application (BLA)
Oncology Biomarker Qualification Initiative
The "Cancer Vaccines Markets" report
examines companies manufacturing cancer
vaccines equipment and supplies in the world.
Companies covered include:
Advaxis, Agenus (formerly Antigenics),
Alphavax, Antigen Express, Apthera, Argos, AVAX, Bavarian Nordic, Bellicum, BioSante, Biovest,
Celldex, CG, CureVac, DanDrit, Dendreon,
EMD Serono, Geron, Glaxosmithkline,
Globeimmune, Immatics, ImmunoCellular,
Immunovaccine, Inovio, KAEL-Gemvax, MannKind, Mologen, NewLink Genetics, Northwest, NovaRx,
Oxford BioMedica, Prima BioMed, Scancell,
Transgene, Trimed, Vaccinogen and Vical.
http://opensource.sys-con.com/node/1788657
- Forums
- ASX - By Stock
- IMM
- nothing to do with th sp
nothing to do with th sp
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M |
Open | High | Low | Value | Volume |
31.0¢ | 31.5¢ | 30.5¢ | $251.5K | 806.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 121215 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 2864 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 121215 | 0.310 |
21 | 282998 | 0.305 |
21 | 464160 | 0.300 |
6 | 89833 | 0.295 |
11 | 293135 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 2864 | 3 |
0.320 | 175639 | 5 |
0.325 | 392741 | 5 |
0.330 | 168348 | 4 |
0.335 | 196676 | 5 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |